Literature DB >> 9449693

Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor.

N J Horwood1, N Udagawa, J Elliott, D Grail, H Okamura, M Kurimoto, A R Dunn, T Martin, M T Gillespie.   

Abstract

IL-18 inhibits osteoclast (OCL) formation in vitro independent of IFN-gamma production, and this was abolished by the addition of neutralizing antibodies to GM-CSF. We now establish that IL-18 was unable to inhibit OCL formation in cocultures using GM-CSF-deficient mice (GM-CSF -/-). Reciprocal cocultures using either wild-type osteoblasts with GM-CSF -/- spleen cells or GM-CSF -/- osteoblasts with wild-type spleen cells were examined. Wild-type spleen cells were required to elicit a response to IL-18 indicating that cells of splenic origin were the IL-18 target. As T cells comprise a large proportion of the spleen cell population, the role of T cells in osteoclastogenesis was examined. Total T cells were removed and repleted in various combinations. Addition of wild-type T cells to a GM-CSF -/- coculture restored IL-18 inhibition of osteoclastogenesis. Major subsets of T cells, CD4+ and CD8+, were also individually depleted. Addition of either CD4+ or CD8+ wild-type T cells restored IL-18 action in a GM-CSF -/- background, while IL-18 was ineffective when either CD4+ or CD8+ GM-CSF -/- T cells were added to a wild-type coculture. These results highlight the involvement of T cells in IL-18-induced OCL inhibition and provide evidence for a new OCL inhibitory pathway whereby IL-18 inhibits OCL formation due to action upon T cells promoting the release of GM-CSF, which in turn acts upon OCL precursors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9449693      PMCID: PMC508603          DOI: 10.1172/JCI1333

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  T lymphocyte surface antigen markers in osteoporosis.

Authors:  C J Rosen; K Usiskin; M Owens; C O Barlascini; M Belsky; R A Adler
Journal:  J Bone Miner Res       Date:  1990-08       Impact factor: 6.741

2.  Interleukin-18 activates NF-kappaB in murine T helper type 1 cells.

Authors:  S Matsumoto; K Tsuji-Takayama; Y Aizawa; K Koide; M Takeuchi; T Ohta; M Kurimoto
Journal:  Biochem Biophys Res Commun       Date:  1997-05-19       Impact factor: 3.575

3.  The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells.

Authors:  N Udagawa; N Takahashi; T Akatsu; T Sasaki; A Yamaguchi; H Kodama; T J Martin; T Suda
Journal:  Endocrinology       Date:  1989-10       Impact factor: 4.736

4.  Osteoblastic cells are involved in osteoclast formation.

Authors:  N Takahashi; T Akatsu; N Udagawa; T Sasaki; A Yamaguchi; J M Moseley; T J Martin; T Suda
Journal:  Endocrinology       Date:  1988-11       Impact factor: 4.736

5.  Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration.

Authors:  C Movsowitz; S Epstein; M Fallon; F Ismail; S Thomas
Journal:  Endocrinology       Date:  1988-11       Impact factor: 4.736

6.  Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology.

Authors:  E Stanley; G J Lieschke; D Grail; D Metcalf; G Hodgson; J A Gall; D W Maher; J Cebon; V Sinickas; A R Dunn
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

7.  The clonal proliferation of normal mouse hematopoietic cells: enhancement and suppression by colony-stimulating factor combinations.

Authors:  D Metcalf; N A Nicola
Journal:  Blood       Date:  1992-06-01       Impact factor: 22.113

8.  Cytokine production and surface antigen expression by peripheral blood mononuclear cells in postmenopausal osteoporosis.

Authors:  F G Hustmyer; E Walker; X P Yu; G Girasole; Y Sakagami; M Peacock; S C Manolagas
Journal:  J Bone Miner Res       Date:  1993-01       Impact factor: 6.741

Review 9.  Histiocytes and histiocytosis.

Authors:  M J Cline
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

10.  Resorption of bone by isolated rabbit osteoclasts.

Authors:  T J Chambers; P A Revell; K Fuller; N A Athanasou
Journal:  J Cell Sci       Date:  1984-03       Impact factor: 5.285

View more
  37 in total

Review 1.  Interleukin-18, rheumatoid arthritis, and tissue destruction.

Authors:  J M Dayer
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 2.  Pathogenesis of postmenopausal osteoporosis.

Authors:  L G Raisz
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

3.  IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis.

Authors:  S Kotake; N Udagawa; N Takahashi; K Matsuzaki; K Itoh; S Ishiyama; S Saito; K Inoue; N Kamatani; M T Gillespie; T J Martin; T Suda
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

Review 4.  Interleukin-18 as a potential target in inflammatory arthritis.

Authors:  J A Gracie
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

Review 5.  Mediators of inflammation and bone remodeling in rheumatic disease.

Authors:  Anita T Shaw; Ellen M Gravallese
Journal:  Semin Cell Dev Biol       Date:  2015-10-19       Impact factor: 7.727

Review 6.  Osteoblast responses to bacterial pathogens: a previously unappreciated role for bone-forming cells in host defense and disease progression.

Authors:  Ian Marriott
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 7.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

Review 8.  APC-derived cytokines and T cell polarization in autoimmune inflammation.

Authors:  Ilona Gutcher; Burkhard Becher
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  Osteoclast inhibitory lectin, an immune cell product that is required for normal bone physiology in vivo.

Authors:  Vicky Kartsogiannis; Natalie A Sims; Julian M W Quinn; Chi Ly; Mirijana Cipetic; Ingrid J Poulton; Emma C Walker; Hasnawati Saleh; Narelle E McGregor; Morgan E Wallace; Mark J Smyth; T John Martin; Hong Zhou; Kong Wah Ng; Matthew T Gillespie
Journal:  J Biol Chem       Date:  2008-09-08       Impact factor: 5.157

Review 10.  Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis.

Authors:  Iain B McInnes; J Alastair Gracie
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.